Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $481.31 million. The enterprise value is $307.22 million.
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, after market close.
Earnings Date | Oct 29, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
LAB has 382.00 million shares outstanding. The number of shares has increased by 82.38% in one year.
Current Share Class | 382.00M |
Shares Outstanding | 382.00M |
Shares Change (YoY) | +82.38% |
Shares Change (QoQ) | +0.60% |
Owned by Insiders (%) | 1.53% |
Owned by Institutions (%) | 47.50% |
Float | 240.01M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.97 |
Forward PS | 6.61 |
PB Ratio | 1.22 |
P/TBV Ratio | 1.21 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.78 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.16, with a Debt / Equity ratio of 0.07.
Current Ratio | 5.16 |
Quick Ratio | 2.57 |
Debt / Equity | 0.07 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -96.06 |
Financial Efficiency
Return on equity (ROE) is -29.54% and return on invested capital (ROIC) is -16.36%.
Return on Equity (ROE) | -29.54% |
Return on Assets (ROA) | -13.62% |
Return on Invested Capital (ROIC) | -16.36% |
Return on Capital Employed (ROCE) | -30.06% |
Revenue Per Employee | $210,600 |
Profits Per Employee | -$147,313 |
Employee Count | 818 |
Asset Turnover | 0.27 |
Inventory Turnover | 2.63 |
Taxes
Income Tax | -307,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.90% in the last 52 weeks. The beta is 1.29, so LAB's price volatility has been higher than the market average.
Beta (5Y) | 1.29 |
52-Week Price Change | -29.90% |
50-Day Moving Average | 1.30 |
200-Day Moving Average | 1.35 |
Relative Strength Index (RSI) | 59.67 |
Average Volume (20 Days) | 1,255,053 |
Short Selling Information
The latest short interest is 12.54 million, so 3.28% of the outstanding shares have been sold short.
Short Interest | 12.54M |
Short Previous Month | 12.01M |
Short % of Shares Out | 3.28% |
Short % of Float | 5.22% |
Short Ratio (days to cover) | 9.06 |
Income Statement
In the last 12 months, LAB had revenue of $172.27 million and -$120.50 million in losses. Loss per share was -$0.32.
Revenue | 172.27M |
Gross Profit | 84.54M |
Operating Income | -137.94M |
Pretax Income | -118.58M |
Net Income | -120.50M |
EBITDA | -121.81M |
EBIT | -137.94M |
Loss Per Share | -$0.32 |
Full Income Statement Balance Sheet
The company has $237.09 million in cash and $28.62 million in debt, giving a net cash position of $208.47 million or $0.55 per share.
Cash & Cash Equivalents | 237.09M |
Total Debt | 28.62M |
Net Cash | 208.47M |
Net Cash Per Share | $0.55 |
Equity (Book Value) | 424.54M |
Book Value Per Share | 1.11 |
Working Capital | 408.01M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$92.88 million and capital expenditures -$12.58 million, giving a free cash flow of -$105.46 million.
Operating Cash Flow | -92.88M |
Capital Expenditures | -12.58M |
Free Cash Flow | -105.46M |
FCF Per Share | -$0.28 |
Full Cash Flow Statement Margins
Gross margin is 49.07%, with operating and profit margins of -80.07% and -69.95%.
Gross Margin | 49.07% |
Operating Margin | -80.07% |
Pretax Margin | -80.33% |
Profit Margin | -69.95% |
EBITDA Margin | -70.71% |
EBIT Margin | -80.07% |
FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -82.38% |
Shareholder Yield | -82.38% |
Earnings Yield | -23.37% |
FCF Yield | -20.45% |
Analyst Forecast
The average price target for LAB is $2.50, which is 98.41% higher than the current price. The consensus rating is "Buy".
Price Target | $2.50 |
Price Target Difference | 98.41% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | -15.66% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of -0.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.07 |
Piotroski F-Score | 3 |